Methods and composition for neutralization of influenza
AssigneeThe University of Chicago
InventorsPatrick C. WILSON, Carole J. Henry DUNAND
Life of this patent
Estimating the term…
Abstract
Provided herein are compositions useful for neutralization of influenza virus, and methods of use and manufacture thereof. In particular, compositions comprising antibodies that are cross-reactive with multiple influenza strains are provided, as well as methods of treatment and prevention of influenza infection therewith.
Claims50
A binding agent comprising:
- (a) a polypeptide comprising a region having at least 70% sequence identity with a polypeptide encoded by one of SEQ ID NOs. 1-3 and 33;
- and
- (b) a polypeptide comprising a region having at least 70% sequence identity with a polypeptide encoded by one of SEQ ID NOs. 4-6 and 34;
- wherein the binding agent exhibits similar influenza epitope-binding characteristics to an antibody comprising a heavy and light chain variable regions with 100% sequence identity to those encoded by one of SEQ ID NOs:
- 1:4, 2:5, 3:6, or 33:34, respectively.
A polynucleotide comprising a potion with 70% or greater sequence identity with one or more of SEQ ID NOs:
- 1-6 and 33-34.
A method of treating or preventing an H7 influenza virus infection comprising administering to a first subject an antibody generated by vaccination of a second subject with a vaccine against an H1 and/or H3 infection.
A binding agent that neutralizes infection of an H7 strain of influenza A virus and an H1 or H3 strain of influenza and binds the same epitope as one of:
- (i) the heavy chain variable sequence set forth in SEQ ID NO:
- 7, and the light chain variable sequence set forth in SEQ ID NO:
- 10;
- or (ii) the heavy chain variable sequence set forth in SEQ ID NO:
- 8, and the light chain variable sequence set forth in SEQ ID NO:
- 11;
- or (iii) the heavy chain variable sequence set forth in SEQ ID NO:
- 9, and the light chain variable sequence set forth in SEQ ID NO:
- 12;
- or (iv) the heavy chain variable sequence set forth in SEQ ID NO:
- 35, and the light chain variable sequence set forth in SEQ ID NO:
- 36.
A binding agent that neutralizes infection of an H7 strain of influenza A virus and an H1 or H3 strain of influenza an binds the same epitope as one of:
- (i) the heavy chain CDR1, CDR2 and CDR3 sequences as set forth in SEQ ID NOs:
- 13, 14 and 15, respectively, and the light chain CDR1, CDR2, and CDR3 sequences as set forth in SEQ ID NOs:
- 22, 23 and 24, respectively;
- or (ii) the heavy chain CDR1, CDR2 and CDR3 sequences as set forth in SEQ ID NOs:
- 16, 17 and 18, respectively, and the light chain CDR1, CDR2, and CDR3 sequences as set forth in SEQ ID NOs:
- 25, 26 and 27, respectively;
- or (iii) the heavy chain CDR1, CDR2 and CDR3 sequences as set forth in SEQ ID NOs:
- 19, 20 and 21, respectively, and the light chain CDR1, CDR2, and CDR3 sequences as set forth in SEQ ID NOs:
- 28, 29 and 30, respectively;
- or (iv) the heavy chain CDR1, CDR2 and CDR3 sequences as set forth in SEQ ID NOs:
- 37, 38 and 39, respectively, and the light chain CDR1, CDR2, and CDR3 sequences as set forth in SEQ ID NOs:
- 40, 41 and 42, respectively.
A binding agent comprising:
- (a) a polypeptide comprising a region having at least 70-% sequence identity with one of SEQ ID NOs. 7-9 and 35;
- and
- (b) a polypeptide comprising a region having at least 70% sequence identity with one of SEQ ID NOs. 10-12 and 36;
- wherein the binding agent exhibits similar influenza epitope-binding characteristics to an antibody comprising a heavy and light chain variable regions with 100% sequence identity to those encoded by one of SEQ ID NOs:
- 7:10, 8:11, 9:12, or 35:36, respectively.
A binding agent comprising:
- an HCDR1 of SEQ ID NO:
- 13;
- an HCDR2 of SEQ ID NO:
- 14;
- an HCDR3 of SEQ ID NO:
- 15;
- a KCDR1 of SEQ ID NO:
- 22;
- a KCDR2 of SEQ ID NO:
- 23;
- and a KCDR3 of SEQ ID NO:
- 24.
A binding agent comprising:
- an HCDR1 of SEQ ID NO:
- 16;
- an HCDR2 of SEQ ID NO:
- 17;
- an HCDR3 of SEQ ID NO:
- 18;
- a KCDR1 of SEQ ID NO:
- 25;
- a KCDR2 of SEQ ID NO:
- 26;
- and a KCDR3 of SEQ ID NO:
- 27.
A binding agent comprising:
- an HCDR1 of SEQ ID NO:
- 19;
- an HCDR2 of SEQ ID NO:
- 20;
- an HCDR3 of SEQ ID NO:
- 21;
- a KCDR1 of SEQ ID NO:
- 28;
- a KCDR2 of SEQ ID NO:
- 29;
- and a KCDR3 of SEQ ID NO:
- 30.
A binding agent comprising:
- an HCDR1 of SEQ ID NO:
- 37;
- an HCDR2 of SEQ ID NO:
- 38;
- an HCDR3 of SEQ ID NO:
- 39;
- a KCDR1 of SEQ ID NO:
- 40;
- a KCDR2 of SEQ ID NO:
- 41;
- and a KCDR3 of SEQ ID NO:
- 42.
An antigen binding agent comprising complementarity determining regions (CDRs) of the variable region of the heavy chain comprising at least 70% sequence identity to the following amino acid sequences:
- an HCDR1 of SEQ ID NO:
- 13;
- an HCDR2 of SEQ ID NO:
- 14;
- an HCDR3 of SEQ ID NO:
- 15;
- and comprising CDRs of the variable region of the light chain comprising at least 70% sequence identity to the following amino acid sequences:
- a KCDR1 of SEQ ID NO:
- 22;
- a KCDR2 of SEQ ID NO:
- 23;
- and a KCDR3 of SEQ ID NO:
- 24.
An antigen binding agent comprising complementarity determining regions (CDRs) of the variable region of the heavy chain comprising at least 70% sequence identity to the following amino acid sequences:
- an HCDR1 of SEQ ID NO:
- 16;
- an HCDR2 of SEQ ID NO:
- 17;
- an HCDR3 of SEQ ID NO:
- 18;
- and comprising CDRs of the variable region of the light chain comprising at least 70% sequence identity to the following amino acid sequences:
- a KCDR1 of SEQ ID NO:
- 25;
- a KCDR2 of SEQ ID NO:
- 26;
- and a KCDR3 of SEQ ID NO:
- 27.
An antigen binding agent comprising complementarity determining regions (CDRs) of the variable region of the heavy chain comprising at least 70% sequence identity to the following amino acid sequences:
- an HCDR1 of SEQ ID NO:
- 18;
- an HCDR2 of SEQ ID NO:
- 19;
- an HCDR3 of SEQ ID NO:
- 20;
- and comprising CDRs of the variable region of the light chain comprising at least 70% sequence identity to the following amino acid sequences:
- a KCDR1 of SEQ ID NO:
- 28;
- a KCDR2 of SEQ ID NO:
- 29;
- and a KCDR3 of SEQ ID NO:
- 30.
An antigen binding agent comprising complementarity determining regions (CDRs) of the variable region of the heavy chain comprising at least 70% sequence identity to the following amino acid sequences:
- an HCDR1 of SEQ ID NO:
- 37;
- an HCDR2 of SEQ ID NO:
- 38;
- an HCDR3 of SEQ ID NO:
- 39;
- and comprising CDRs of the variable region of the light chain comprising at least 70% sequence identity to the following amino acid sequences:
- a KCDR1 of SEQ ID NO:
- 40;
- a KCDR2 of SEQ ID NO:
- 41;
- and a KCDR3 of SEQ ID NO:
- 42.
An antigen binding agent comprising complementarity determining regions (CDRs) having at least 70% sequence identity to the following amino acid sequences:
- a first CDR1 of SEQ ID NO:
- 13;
- a first CDR2 of SEQ ID NO:
- 14;
- a first CDR3 of SEQ ID NO:
- 15, a second CDR1 of SEQ ID NO:
- 22;
- a second CDR2 of SEQ ID NO:
- 23;
- and a second CDR3 of SEQ ID NO:
- 24.
An antigen binding agent comprising complementarity determining regions (CDRs) of having at least 70% sequence identity to the following amino acid sequences:
- a first CDR1 of SEQ ID NO:
- 16;
- a first CDR2 of SEQ ID NO:
- 17;
- a first CDR3 of SEQ ID NO:
- 18, a second CDR1 of SEQ ID NO:
- 25;
- a second CDR2 of SEQ ID NO:
- 26;
- and a second CDR3 of SEQ ID NO:
- 27.
An antigen binding agent comprising complementarity determining regions (CDRs) having at least 70% sequence identity to the following amino acid sequences:
- a first CDR1 of SEQ ID NO:
- 18;
- a first CDR2 of SEQ ID NO:
- 19;
- a first CDR3 of SEQ ID NO:
- 20, a second CDR1 of SEQ ID NO:
- 28;
- a second CDR2 of SEQ ID NO:
- 29;
- and a second CDR3 of SEQ ID NO:
- 30.
An antigen binding agent comprising complementarity determining regions (CDRs) having at least 70% sequence identity to the following amino acid sequences:
- a first CDR1 of SEQ ID NO:
- 37;
- a first CDR2 of SEQ ID NO:
- 38;
- a first CDR3 of SEQ ID NO:
- 39, a second CDR1 of SEQ ID NO:
- 40, a second CDR2 of SEQ ID NO:
- 41, and a second CDR3 of SEQ ID NO:
- 42.
Dependencies are inferred from the claim text.